Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis | Zendy

Imtiaz A. Samjoo | Zendy; Evelyn Worthington | Zendy; Christopher Drudge | Zendy; Melody Zhao | Zendy; Chris Cameron | Zendy; Dieter A. Häring | Zendy; Dee Stoneman | Zendy; Luisa Klotz | Zendy; Nicholas Adlard | Zendy

Open Access

Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

Author(s) -

Imtiaz A. Samjoo,

Evelyn Worthington,

Christopher Drudge,

Melody Zhao,

Chris Cameron,

Dieter A. Häring,

Dee Stoneman,

Luisa Klotz,

Nicholas Adlard

Publication year - 2020

Publication title -

journal of comparative effectiveness research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.567

H-Index - 23

eISSN - 2042-6313

pISSN - 2042-6305

DOI - 10.2217/cer-2020-0122

Subject(s) - ofatumumab , medicine , natalizumab , ocrelizumab , alemtuzumab , multiple sclerosis , meta analysis , oncology , disease , immunology , rituximab , transplantation , lymphoma

Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research